Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

13 Issues per year

IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046



Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis

Nicola Bizzaro1


Corresponding author: Nicola Bizzaro, MD, Laboratorio di Patologia Clinica, Ospedale Civile, Via Morgagni, 18, 33028 Tolmezzo (UD), Italy Phone: +39-0433-488261, Fax: +39-0433-488697,

Citation Information: Clinical Chemical Laboratory Medicine. Volume 45, Issue 2, Pages 150–157, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2007.027, February 2007

Publication History

August 17, 2006
October 12, 2006
Published Online:


The early diagnosis of rheumatoid arthritis (RA) has become a priority owing to the availability of effective disease-modifying agents that can improve patient wellbeing and influence the clinical outcome. However, this represents a real challenge, as no clinical, radiological or immunological features are pathognomonic at the time of presentation. For this reason, development of the anti-cyclic citrullinated peptide (CCP) antibody assay, a highly disease-specific serological marker for RA, has been a great step forward for the rheumatologist and the clinical laboratory. Over recent years, this test has increased in popularity and many studies have been performed. This review briefly considers the most recent data on the diagnostic accuracy of the CCP test, the genetic background that predisposes to antibody production, the diagnostic, prognostic and predictive values, and the clinical use of the assay in patients with RA.

Clin Chem Lab Med 2007;45:150–7.

Keywords: anti-cyclic citrullinated peptide (CCP) antibodies; citrullinated peptides; filaggrin; rheumatoid arthritis

Comments (0)

Please log in or register to comment.